6-Oxo-1,6-dihydropyridazine-3-carbaldehyde

Catalog No.: 
ACJWEG143
CAS No.: 
933734-91-9
Molecular Formula: 
C5H4N2O2
Molecular Weight: 
124.10
6-Oxo-1,6-dihydropyridazine-3-carbaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$58.00In stockIn stock
1g95%$115.00In stockIn stock
5g95%$527.00In stockIn stock
25g95%$1939.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Oxo-1,6-dihydropyridazine-3-carbaldehyde
IUPAC Name6-oxo-1,6-dihydropyridazine-3-carbaldehyde
MDL No.MFCD09998728
Molecular FormulaC5H4N2O2
Molecular Weight124.10
SMILESO=CC(C=C1)=NNC1=O
InChI KeyNRSDBRGRLFTCSW-UHFFFAOYSA-N
SynonymC77199 | SCHEMBL14919309 | EN300-2913996 | 6-hydroxypyridazine-3-carbaldehyde | PS-4209 | 6-Oxo-1,6-dihydropyridazine-3-carbaldehyde | A916348 | MFCD09998728 | 1,6-DIHYDRO-6-OXO-3-PYRIDAZINECARBOXALDEHYDE | DTXSID40653296 | AKOS006229327 | 6-Oxo-1,6-dihyd
CAS No.933734-91-9
PubChem CID37818559

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H312-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACJWEG143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACPEVO512 route compound structure diagram
    ACPEVO51237972-69-3In Stock
  2. Then
  3. ACJWEG143 route product structure diagram
    ACJWEG143933734-91-9In Stock
Inquiry

2. ACJWEG143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJWEG143 route product structure diagram
    ACJWEG143933734-91-9In Stock
Inquiry

3. ACJWEG143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJWEG143 route product structure diagram
    ACJWEG143933734-91-9In Stock
Inquiry

Comments (0)